SDZ 220-581 Ammonium salt

Cat. No.:	HY-13059A
CAS No.:	179411-94-0
Molecular Formula:	$C_{16}H_{20}ClN_2O_5P$
Molecular Weight:	386.77
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	SDZ 220-581 Ammonium salt is an orally active, potent, competitive NMDA receptor antagonist with pK_i value of 7.7[1].
IC_{50} & Target	pKi: 7.7 (NMDA receptor)[1]
In Vivo	SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male OF-l mice (18-26 g)[1]
Dosage:	3.2 mg/kg, 10 mg/kg, 32 mg/kg
Administration:	Oral administration; for 24 hours
Result:	Dose-dependently protected mice against maximal electroshock seizures (MES) upon oral administration.

REFERENCES

[1]. Urwyler S, et al. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69.

[2]. Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the $mGlu_5$ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA